BACKGROUND: Virological failure of first-generation nonnucleoside reverse transcriptase inhibitors (NNRTIs) can compromise the efficacy of etravirine as a result of the accumulation of NNRTI resistance mutations. How quickly NNRTI resistance accumulates in patients with a delayed switch from nevirapine or efavirenz despite virological failure, when these drugs are used as a component of combination antiretroviral therapy (cART), remains unclear. METHODS: The rate of NNRTI resistance accumulation was estimated in patients in EuroSIDA with at least two available genotypic resistance tests (GRTs), provided that (1) the date of the first GRT (t0) was after the date of the first virological failure (VF) of an NNRTI, and (2) patients were receiving an NNRTI and HIV RNA was >500 HIV-1 RNA copies/mL in all measurements between GRTs. RESULTS: A total of 227 patients were included in the study, contributing 467 GRT pairs. At baseline-t0, a median of 3 months after VF, 66% of patients had at least one NNRTI mutation: 103N (34%), 181C (22%) and 190A (20%) were the most common mutations. Overall, 180 additional NNRTI mutations were found to have accumulated over 295 years [1 new/1.6 years; 95% confidence interval (CI) 1.5-1.8]. The rate of accumulation was faster in the first 6 months from VF (1 new/1.1 years), and slower in patients exposed to nevirapine vs. those receiving efavirenz [relative risk (RR) 0.66; 95% CI 0.46-0.95; P=0.03]. CONCLUSIONS: There is an initial phase of rapid accumulation of NNRTI mutations close to the time of VF followed by a phase of slower accumulation. We predict that it should take approximately one year of exposure to a virologically failing first-generation NNRTI-based cART regimen to reduce etravirine activity from fully susceptible to intermediate resistant, and possibly longer in patients kept on a failing nevirapine-containing regimen.
BACKGROUND: Virological failure of first-generation nonnucleoside reverse transcriptase inhibitors (NNRTIs) can compromise the efficacy of etravirine as a result of the accumulation of NNRTI resistance mutations. How quickly NNRTI resistance accumulates in patients with a delayed switch from nevirapine or efavirenz despite virological failure, when these drugs are used as a component of combination antiretroviral therapy (cART), remains unclear. METHODS: The rate of NNRTI resistance accumulation was estimated in patients in EuroSIDA with at least two available genotypic resistance tests (GRTs), provided that (1) the date of the first GRT (t0) was after the date of the first virological failure (VF) of an NNRTI, and (2) patients were receiving an NNRTI and HIV RNA was >500 HIV-1 RNA copies/mL in all measurements between GRTs. RESULTS: A total of 227 patients were included in the study, contributing 467 GRT pairs. At baseline-t0, a median of 3 months after VF, 66% of patients had at least one NNRTI mutation: 103N (34%), 181C (22%) and 190A (20%) were the most common mutations. Overall, 180 additional NNRTI mutations were found to have accumulated over 295 years [1 new/1.6 years; 95% confidence interval (CI) 1.5-1.8]. The rate of accumulation was faster in the first 6 months from VF (1 new/1.1 years), and slower in patients exposed to nevirapine vs. those receiving efavirenz [relative risk (RR) 0.66; 95% CI 0.46-0.95; P=0.03]. CONCLUSIONS: There is an initial phase of rapid accumulation of NNRTI mutations close to the time of VF followed by a phase of slower accumulation. We predict that it should take approximately one year of exposure to a virologically failing first-generation NNRTI-based cART regimen to reduce etravirine activity from fully susceptible to intermediate resistant, and possibly longer in patients kept on a failing nevirapine-containing regimen.
Authors: Awachana Jiamsakul; Azar Kariminia; Keri N Althoff; Carina Cesar; Claudia P Cortes; Mary-Ann Davies; Viet Chau Do; Brian Eley; John Gill; Nagalingeswaran Kumarasamy; Daisy Maria Machado; Richard Moore; Hans Prozesky; Elizabeth Zaniewski; Matthew Law Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Isaac Singini; Thomas B Campbell; Laura M Smeaton; Nagalingeswaran Kumarasamy; Alberto La Rosa; Sineenart Taejareonkul; Steven A Safren; Timothy P Flanigan; James G Hakim; Michael D Hughes Journal: HIV Clin Trials Date: 2016-07-29
Authors: Philip J Palumbo; Jessica M Fogel; Sarah E Hudelson; Ethan A Wilson; Stephen Hart; Laura Hovind; Estelle Piwowar-Manning; Carole Wallis; Maria A Papathanasopoulos; Mariza G Morgado; Shanmugam Saravanan; Srikanth Tripathy; Joseph J Eron; Joel E Gallant; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Jose H Pilotto; Johnstone Kumwenda; Victor Akelo; Sheela V Godbole; Breno R Santos; Beatriz Grinsztejn; Ravindre Panchia; Suwat Chariyalertsak; Joseph Makhema; Sharlaa Badal-Faesen; Ying Q Chen; Myron S Cohen; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2018-04-15 Impact factor: 3.731
Authors: Zahra Reynolds; Suzanne M McCluskey; Mahomed Yunus S Moosa; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin L Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Pravi Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent A Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi; Mwebesa Bosco Bwana; Mark J Siedner Journal: HIV Med Date: 2021-11-09 Impact factor: 3.094
Authors: Cissy Kityo; Jennifer Thompson; Immaculate Nankya; Anne Hoppe; Emmanuel Ndashimye; Colin Warambwa; Ivan Mambule; Joep J van Oosterhout; Kara Wools-Kaloustian; Silvia Bertagnolio; Philippa J Easterbrook; Peter Mugyenyi; A Sarah Walker; Nicholas I Paton Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Denise Kühnert; Roger Kouyos; George Shirreff; Jūlija Pečerska; Alexandra U Scherrer; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Huldrych F Günthard; Tanja Stadler; Sebastian Bonhoeffer Journal: PLoS Pathog Date: 2018-02-20 Impact factor: 6.823
Authors: Adriaan E Basson; Soo-Yon Rhee; Chris M Parry; Ziad El-Khatib; Salome Charalambous; Tulio De Oliveira; Deenan Pillay; Christopher Hoffmann; David Katzenstein; Robert W Shafer; Lynn Morris Journal: Antimicrob Agents Chemother Date: 2014-11-24 Impact factor: 5.191
Authors: Alemseged Abdissa; Daniel Yilma; Jannik Fonager; Anne M Audelin; Lone H Christensen; Mette F Olsen; Markos Tesfaye; Pernille Kaestel; Tsinuel Girma; Abraham Aseffa; Henrik Friis; Court Pedersen; Aase B Andersen Journal: BMC Infect Dis Date: 2014-04-04 Impact factor: 3.090